Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal‐related relapse

Neuroleptic Withdrawal in Schizophrenic Patients

Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434 · see citing works

Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder

Suppes, T. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360046007 · Cited by 392 · see citing works

Antidepressant-Induced Sexual Dysfunction

Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320 · see citing works

Increased dopamine D 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study

Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311 · see citing works

Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics

(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301 · see citing works

Dopaminergic supersensitivity after neuroleptics: time-course and specificity

Muller, P., & Seeman, P. (1978) · Psychopharmacology · doi:10.1007/bf00429171 · Cited by 271 · see citing works

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment

Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246 · cited 7× · see citing works

Rapid Release of Antipsychotic Drugs From Dopamine D₂ Receptors: An Explanation for Low Receptor Occupancy and Early Clinical Relapse Upon Withdrawal of Clozapine or Quetiapine

Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237 · see citing works

Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia

Gitlin, M. J., Nuechterlein, K. H., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1835 · Cited by 217 · see citing works

Neuroleptic Withdrawal in Schizophrenic Patients

Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 194 · see citing works

Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia

Gitlin, M. J., Nuechterlein, K. H., Subotnik, K. L., Ventura, J., Mintz, J., Fogelson, D. L., Bartzokis, G., & Aravagiri, M. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.1.122 · Cited by 183 · see citing works

Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications

Baldessarini, R. J., Tondo, L., & Viguera, A. C. (1999) · Bipolar Disorders · doi:10.1034/j.1399-5618.1999.10106.x · Cited by 152 · see citing works

Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?

Lehtinen, V., Aaltonen, J., Koffert, T., Räkköläinen, V., & Syvälahti, E. K. G. (2000) · European Psychiatry · doi:10.1016/s0924-9338(00)00400-4 · Cited by 137 · see citing works

First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies

Gäebel, W., Jänner, M., Frommann, N., Pietźcker, A., Köpcke, W., Linden, M., Müller, P., Müller-Spahn, F., & Tegeler, J. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00182-7 · Cited by 133 · see citing works

Severe cases of neuroleptic-induced supersensitivity psychosis

Chouinard, G. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90050-2 · Cited by 123 · see citing works

Diazepam Treatment of Early Signs of Exacerbation in Schizophrenia

Carpenter, W. T., Buchanan, R. W., Kirkpatrick, B. W., & Breier, A. F. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.299 · Cited by 117 · see citing works

A new bipolar spectrum concept: a brief review

Angst, J., & Gamma, A. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.4.s1.1.x · Cited by 111 · see citing works

Drs. Chouinard and Jones Reply

Chouinard, G., & JONES, B. D. (1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.8.992-a · Cited by 105 · see citing works

Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal

Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104 · see citing works

The Natural Course of Schizophrenia and Effective Maintenance Drug Treatment

Davis, J. M., & Andriukaitis, S. M. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198602001-00002 · Cited by 98 · see citing works

Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal

Ekblom, B., Eriksson, K., & Lindstr�m, L. H. (1984) · Psychopharmacology · doi:10.1007/bf00464798 · Cited by 88 · see citing works

Clozapine Withdrawal Resulting in Delirium With Psychosis

Stanilla, J. K., de León, J., & Simpson, G. M. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0603 · Cited by 87 · see citing works

Psychopathology Induced by “Speed Drugs”

Schiørring, E. (1981) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(81)80018-4 · Cited by 87 · see citing works

Practical Psychiatric Epidemiology

(2003) · Oxford University Press eBooks · doi:10.1093/med/9780198515517.001.0001 · Cited by 87 · see citing works

A Randomized, Placebo-Controlled Trial of the Discontinuation of Long-Term Antipsychotics in Dementia

van Reekum, R., Conn, D. K., Clarke, D. E., Cohen, T., Ostrander, L., Herrmann, N., & Eryavec, G. M. (2002) · International Psychogeriatrics · doi:10.1017/s1041610202008396 · Cited by 74 · see citing works

WITHDRAWAL FROM NEUROLEPTIC DRUGS

Brooks, G. W. (1959) · American Journal of Psychiatry · doi:10.1176/ajp.115.10.931 · Cited by 73 · see citing works

Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine

Meltzer, H. Y., Lee, M. A., Ranjan, R., Mason, E. A., & Cola, P. A. (1996) · Psychopharmacology · doi:10.1007/bf02245619 · Cited by 68 · see citing works

Therapeutic Tolerance and Rebound Psychosis During Quetiapine Maintenance Monotherapy in Patients With Schizophrenia and Schizoaffective Disorder

Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61 · see citing works

Antipsychotic augmentation for treatment resistant obsessive???compulsive disorder: what if antipsychotic is discontinued?

Maina, G., Albert, U., Ziero, S., & Bogetto, F. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000047784.24295.2b · Cited by 61 · see citing works

Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics

Verghese, C., de León, J., Nair, C., & Simpson, G. M. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00215-4 · Cited by 59 · see citing works

Pharmacological long-term treatment strategies in first episode schizophrenia

Gäebel, W., Möller, H., Buchkremer, G., Ohmann, C., Riesbeck, M., Wölwer, W., von Wilmsdorff, M., Ronald Bottlender, A., & Klingberg, S. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0509-y · Cited by 57 · see citing works

Clozapine withdrawal rebound psychosis.

Borison, R. L., Diamond, B. I., Sinha, D., Gupta, R. P., & Ajiboye, P. O. (1988) · PubMed · Cited by 56 · see citing works

Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone

Still, D. J., Dorson, P. G., Crismon, M. L., & Pousson, C. (1996) · Psychiatric Services · doi:10.1176/ps.47.12.1382 · Cited by 54 · see citing works

Rebound psychosis: Effect of discontinuation of antipsychotics in Parkinson's disease

Fernandez, H. H., Trieschmann, M. E., & Okun, M. S. (2004) · Movement Disorders · doi:10.1002/mds.20260 · Cited by 53 · see citing works

Controlled, Double-Blind Investigation of the Clozapine Discontinuation Symptoms With Conversion to Either Olanzapine or Placebo

Tollefson, G. D., Dellva, M. A., Mattler, C. A., Kane, J. M., Wirshing, D. A., & Kinon, B. J. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199910000-00007 · Cited by 50 · see citing works

Neuronal basis of neuroleptic-induced extrapyramidal side effects.

Ossowska, K. (2003) · PubMed · Cited by 48 · see citing works

The effect of lithium in bipolar disorder: a review of recent research evidence

Maj, M. (2003) · Bipolar Disorders · doi:10.1034/j.1399-5618.2003.00002.x · Cited by 46 · see citing works

RESULTS OF SIMULTANEOUS ABRUPT WITHDRAWAL OF ATARAXICS IN 500 CHRONIC PSYCHOTIC PATIENTS

Judah, L. N., JOSEPHS, Z. M., & Murphree, O. D. (1961) · American Journal of Psychiatry · doi:10.1176/ajp.118.2.156 · Cited by 46 · see citing works

Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients.

Chouinard, G., Annable, L., & Ross‐Chouinard, A. (1986) · PubMed · Cited by 45 · see citing works

Is there a limbic system equivalent of tardive dyskinesia?

Kl, D., & Rosenberg, G. S. (1979) · PubMed · Cited by 45 · see citing works

The Concept of Supersensitivity Psychosis

Kirkpatrick, B. W., Alphs, L. D., & Buchanan, R. W. (1992) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199204000-00009 · Cited by 41 · see citing works

Intermittent medication ‐ an alternative?

Gäebel, W. (1994) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1994.tb05863.x · Cited by 32 · see citing works

Conversions From Clozapine to Other Antipsychotic Drugs

Gardner, D. M. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240089014 · Cited by 31 · see citing works

Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.

Llorca, P., Vaïva, G., & Lançon, C. (2001) · PubMed · Cited by 31 · see citing works

Neuroleptic‐induced supersensitivity psychosis in patients with bipolar affective disorder

Steiner, W., Laporta, M., & Chouinard, G. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05477.x · Cited by 26 · see citing works

What is the clinical significance of the discontinuation syndrome seen with clozapine?

Goudie, A. J. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400212 · Cited by 24 · see citing works

Lack of Behavioral Supersensitivity to d-Amphetamine After Pimozide Withdrawal

van Kammen, D. P. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780160057006 · Cited by 23 · see citing works

Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.

Hunt, J. I., Singh, H., & Simpson, G. M. (1988) · PubMed · Cited by 21 · see citing works

Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.

Singh, H., Ji, H., Vitiello, B., & Gm, S. (1990) · PubMed · Cited by 21 · see citing works

Drug Withdrawal in Chronic Schizophrenic Patients

Weinberger, D. R., Bigelow, L. B., KLEIN, S. T., & Wyatt, R. J. (1981) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198105000-00002 · Cited by 20 · see citing works

Reserpine Withdrawal Psychosis

Kent, T. A., & WILBER, R. D. (1982) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198208000-00011 · Cited by 20 · see citing works

Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia.

Diamond, B. I., & Borison, R. L. (1986) · PubMed · Cited by 19 · see citing works

Reserpine withdrawal psychosis: the possible role of denervation supersensitivity of receptors.

Kent, T. A., & Wilber, R. D. (1982) · PubMed · Cited by 18 · see citing works

Psychosis after neuroleptic withdrawal in a manic-depressive patient

(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.1.105 · Cited by 16 · see citing works

Melaine Johns Cupp, Toxicology and Clinical Pharmacology of Herbal Products

Sarker, S. D. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021778358 · Cited by 15 · see citing works

Switching between Clozapine and Risperidone Treatment

Gardner, D. M., Baldessarini, R. J., Benzo, J., Zarate, C. A., & Tohen, M. F. (1997) · The Canadian Journal of Psychiatry · doi:10.1177/070674379704200419 · Cited by 15 · see citing works

Rebound Psychoses following the Discontinuation of a High Potency Neuroleptic

Kahne, G. J. (1989) · The Canadian Journal of Psychiatry · doi:10.1177/070674378903400312 · Cited by 14 · see citing works

Long-term maintenance treatment in chronic schizophrenia. Some observations on outcome and duration.

Johnson, D. A. (1981) · PubMed · Cited by 10 · see citing works

Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis

Apud, J. A., Egan, M. F., & Wyatt, R. J. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00338-9 · Cited by 8 · see citing works

Conventional Antipsychotic Prescription in Unipolar Depression, II

Mortimer, A. M., Martin, M., Vega, J. A. W., & Tyson, P. J. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0608 · Cited by 8 · see citing works

Medical Effects of Abrupt Withdrawal of Neuroleptic Therapy

Lacoursiere, R. B. (1978) · JAMA · doi:10.1001/jama.1978.03290020031010 · Cited by 1 · see citing works

Medical effects of abrupt withdrawal of neuroleptic therapy

Lacoursiere, R. (1978) · JAMA · doi:10.1001/jama.240.2.109c · Cited by 1 · see citing works

The nature of relapse in schizophrenia

Emsley, R. A., Chiliza, B., Asmal, L., & Harvey, B. H. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-50 · Cited by 481 · see citing works

Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders: A Systematic Overview of Meta-analyses

Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.112 · Cited by 333 · see citing works

What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?

Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324 · see citing works

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works

Maintenance treatment with antipsychotic drugs for schizophrenia

Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 287 · see citing works

Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy

Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · see citing works

Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications

Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · see citing works

Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

Murray, R. M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., & Taylor, D. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.182683 · Cited by 244 · see citing works

Early signs, diagnosis and therapeutics of the prodromal phase of schizophrenia and related psychotic disorders

Larson, M. K., Walker, E. F., & Compton, M. T. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.93 · Cited by 203 · see citing works

Maintenance treatment with antipsychotic drugs for schizophrenia

Ceraso, A., Lin, J., Schneider‐Thoma, J., Siafis, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Davis, J. M., & Leucht, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub3 · Cited by 176 · see citing works

Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes

Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168 · see citing works

A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse

Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works

Systematic Review of Clozapine Cardiotoxicity

Curto, M., Girardi, N., Lionetto, L., Ciavarella, G. M., Ferracuti, S., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0704-3 · Cited by 132 · see citing works

Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms

Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115 · see citing works

Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations

Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112 · see citing works

Review of withdrawal catatonia: what does this reveal about clozapine?

Lander, M., Bastiampillai, T. J., & Sareen, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0192-9 · Cited by 109 · see citing works

Does Long-Term Treatment of Schizophrenia With Antipsychotic Medications Facilitate Recovery?

Harrow, M., & Jobe, T. H. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt034 · Cited by 106 · see citing works

Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review

Yin, J., Barr, A. M., Ramos‐Miguel, A., & Procyshyn, R. M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160606093602 · Cited by 97 · see citing works

Mistakes I Have Made in My Research Career

Murray, R. M. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw165 · Cited by 93 · see citing works

Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia

Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.021 · Cited by 81 · see citing works

Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: a systematic review

Sheehan, R., & Hassiotis, A. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30191-2 · Cited by 81 · see citing works

Antipsychotic maintenance treatment: time to rethink

Moncrieff, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001861 · Cited by 80 · see citing works

The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics

Binder, M. D., Sermon, J., Geerts, P., Vansteelandt, K., Peuskens, J., & Detraux, J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0269-4 · Cited by 78 · see citing works

Binding of clozapine to the GABAB receptor: clinical and structural insights

Nair, P. C., McKinnon, R. A., Miners, J. O., & Bastiampillai, T. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0709-5 · Cited by 78 · see citing works

Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies

Ostuzzi, G., Bighelli, I., So, R., Furukawa, T. A., & Barbui, C. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.11.010 · Cited by 78 · see citing works

Prior Antipsychotic Drug Treatment Prevents Response to Novel Antipsychotic Agent in the Methylazoxymethanol Acetate Model of Schizophrenia

Gill, K. M., Cook, J. M., Poe, M. M., & Grace, A. A. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt236 · Cited by 73 · see citing works

Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia

Oda, Y., Kanahara, N., & Iyo, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226228 · Cited by 71 · see citing works

“Extended” Antipsychotic Dosing in the Maintenance Treatment of Schizophrenia

Remington, G. J., Seeman, P. M., Feingold, A., Mann, S. W., Shammi, C., & Kapur, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05866yel · Cited by 65 · see citing works

The evidence-based practice of psychotherapy: Facing the challenges that lie ahead

Gaudiano, B. A., & Miller, I. W. (2013) · Clinical Psychology Review · doi:10.1016/j.cpr.2013.04.004 · Cited by 67 · see citing works

Antipsychotic Dosing: How Much but also How Often?

Remington, G., & Kapur, S. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq083 · Cited by 65 · see citing works

Why is it so difficult to stop psychiatric drug treatment?

Moncrieff, J. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.03.009 · Cited by 59 · see citing works

Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients

Moritz, S., Hocaoglu, C., Karow, A., Deljković, A., Tonn, P., & Naber, D. (2009) · Mental Illness · doi:10.4081/mi.2009.e2 · Cited by 58 · see citing works

A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis

Fallon, P., & Dursun, S. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109359097 · Cited by 56 · see citing works

Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: A systematic review

Cooper, R. E., Laxhman, N., Crellin, N. E., Moncrieff, J., & Priebe, S. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.020 · Cited by 57 · see citing works

A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis

Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.02.022 · Cited by 55 · see citing works

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia

Takase, M., Kanahara, N., Oda, Y., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115570083 · Cited by 54 · see citing works

Clozapine discontinuation withdrawal symptoms in schizophrenia

Blackman, G., & Oloyede, E. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032053 · Cited by 54 · see citing works

Clozapine and GABA transmission in schizophrenia disease models: establishing principles to guide treatments.

O'Connor, W., & O'Shea, S. (2015) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2015.01.005 · Cited by 54 · see citing works

Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders

Harrow, M., Jobe, T. H., & Tong, L. (2021) · Psychological Medicine · doi:10.1017/s0033291720004778 · Cited by 53 · see citing works

Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice

Nakata, Y., Kanahara, N., & Iyo, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117728428 · Cited by 53 · see citing works

Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study

Shah, P., Iwata, Y., Brown, E. E., Kim, J., Sanches, M., Takeuchi, H., Nakajima, S., Hahn, M., Remington, G. J., Gerretsen, P., et al. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01053-6 · Cited by 53 · see citing works

Frontale Hirnvolumenminderung durch Antipsychotika?

Aderhold, V., Weinmann, S., Hägele, C., & Heinz, A. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4027-5 · Cited by 52 · see citing works

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?

Blackman, G., Oloyede, E., Horowitz, M. A., Harland, R., Taylor, D. M., MacCabe, J. H., & McGuire, P. K. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab103 · Cited by 49 · see citing works

Psychotic relapse and associated factors among patients attending health services in Southwest Ethiopia: a cross-sectional study

Fikreyesus, M., Soboka, M., & Feyissa, G. T. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1076-2 · Cited by 48 · see citing works

Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis

Geyt, G. L., Awenat, Y. F., Tai, S., & Haddock, G. (2016) · Qualitative Health Research · doi:10.1177/1049732316634047 · Cited by 47 · see citing works

Antipsychotic-evoked dopamine supersensitivity

Servonnet, A., & Samaha, A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.007 · Cited by 46 · see citing works

Nonadherence to antipsychotics: The role of positive attitudes towards positive symptoms

Moritz, S., Hünsche, A., & Lincoln, T. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.09.008 · Cited by 45 · see citing works

Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review

Thompson, A., Winsper, C., Marwaha, S., Haynes, J., Alvarez-Jimenez, M., Hetrick, S., Realpe, A., Vail, L., Dawson, S., & Sullivan, S. A. (2018) · BJPsych Open · doi:10.1192/bjo.2018.17 · Cited by 44 · see citing works

Re-Visioning Psychiatry

Kirmayer, L. J. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139424745.027 · Cited by 45 · see citing works

An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders

Crellin, N. E., Priebe, S., Morant, N. J., Lewis, G., Freemantle, N., Johnson, S., Horne, R., Pinfold, V., Kent, L., Smith, R., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03822-5 · Cited by 44 · see citing works

Barriers to stopping neuroleptic (antipsychotic) treatment in people with schizophrenia, psychosis or bipolar disorder

Moncrieff, J., Gupta, S., & Horowitz, M. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320937910 · Cited by 43 · see citing works

A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder

Takeuchi, H., & Remington, G. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3154-1 · Cited by 41 · see citing works

Agonist high- and low-affinity states of dopamine D2 receptors: methods of detection and clinical implications

van Wieringen, J., Booij, J., Shalgunov, V., Elsinga, P., & Michel, M. (2012) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-012-0817-0 · Cited by 40 · see citing works

Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial

Huhn, M., Leucht, C., Rothe, P., Dold, M., Heres, S., Bornschein, S., Schneider-Axmann, T., Hasan, A., & Leucht, S. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01109-y · Cited by 38 · see citing works

A Working Hypothesis Regarding Identical Pathomechanisms between Clinical Efficacy and Adverse Reaction of Clozapine via the Activation of Connexin43

Okada, M., Fukuyama, K., Shiroyama, T., & Murata, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197019 · Cited by 38 · see citing works

The neurobiology of relapse in schizophrenia

Remington, G. J., Foussias, G., Agid, O., Fervaha, G., Takeuchi, H., & Hahn, M. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.10.009 · Cited by 38 · see citing works

Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia

Gäebel, W., Riesbeck, M., Wölwer, W., Klimke, A., Eickhoff, M., von Wilmsdorff, M., de Millas, W., Maier, W., Ruhrmann, S., Falkai, P., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.10.024 · Cited by 36 · see citing works

Accumbens D2-MSN hyperactivity drives antipsychotic-induced behavioral supersensitivity

Kruyer, A., Parrilla-Carrero, J., Powell, C., Brandt, L., Gutwinski, S., Angelis, A., Chalhoub, R., Jhou, T. C., Kalivas, P. W., & Amato, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01235-6 · Cited by 36 · see citing works

Deprescribing antipsychotics: a guide for clinicians

Gupta, S., Cahill, J. D., & Miller, R. (2018) · BJPsych Advances · doi:10.1192/bja.2018.2 · Cited by 35 · see citing works

Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence

Emsley, R. A., Nuamah, I. F., Gopal, S., Hough, D. W., & Fleischhacker, W. W. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11874 · Cited by 34 · see citing works

Clonazepam Withdrawal-Induced Catatonia

Brown, M., & Freeman, S. A. (2009) · Psychosomatics · doi:10.1176/appi.psy.50.3.289 · Cited by 34 · see citing works

Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database

Chiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33 · see citing works

Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia

Roy-Desruisseaux, J., Landry, J., Bocti, C., Tessier, D., Hottin, P., & Trudel, J.-F. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1q214 · Cited by 32 · see citing works

A Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With Schizophrenia

Takeuchi, H., Suzuki, T., Uchida, H., Nakajima, S., Nomura, K., Kikuchi, T., Manki, H., Watanabe, K., & Kashima, H. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181842586 · Cited by 33 · see citing works

Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia

Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 33 · see citing works

Could cannabidiol be used as an alternative to antipsychotics?

Fakhoury, M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.05.013 · Cited by 32 · see citing works

Do antipsychotic drugs lose their efficacy for relapse prevention over time?

Leucht, S., & Davis, J. M. (2017) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.117.201103 · Cited by 30 · see citing works

Impact of dopamine supersensitivity psychosis in treatment-resistant schizophrenia: An analysis of multi-factors predicting long-term prognosis

Yamanaka, H., Kanahara, N., Suzuki, T., Takase, M., Moriyama, T., Watanabe, H., Hirata, T., Asano, M., & Iyo, M. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.01.013 · Cited by 29 · see citing works

The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia

Fountoulakis, K., Moeller, H., Kasper, S., Tamminga, C., Yamawaki, S., Kahn, R., Tandon, R., Correll, C., & Javed, A. (2020) · CNS Spectrums · doi:10.1017/s1092852920001546 · Cited by 25 · see citing works

Aripiprazole in combination with other antipsychotic drugs may worsen psychosis

Adán-Manes, J., & García-Parajuá, P. (2008) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.00996.x · Cited by 28 · see citing works

Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up

Kimura, H., Kanahara, N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116655978 · Cited by 26 · see citing works

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

Brasso, C., Bellino, S., Bozzatello, P., Montemagni, C., & Rocca, P. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150568 · Cited by 27 · see citing works

Attempting to discontinue antipsychotic medication: Withdrawal methods, relapse and success

Larsen-Barr, M., Seymour, F. W., Read, J., & Gibson, K. L. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.10.001 · Cited by 27 · see citing works

Effects of drop‐out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia

Hutton, P., Morrison, A. P., Yung, A. R., Taylor, P. J., French, P., & Dunn, G. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01858.x · Cited by 26 · see citing works

The experiences of 585 people when they tried to withdraw from antipsychotic drugs

Read, J. (2022) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2022.100421 · Cited by 24 · see citing works

Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis

Nieman, D. H., Rike, W. H., Becker, H. E., Dingemans, P. M. A. J., van Amelsvoort, T., de Haan, L., van der Gaag, M., Denys, D. A. J. P., & LINSZEN, D. H. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832e0a76 · Cited by 24 · see citing works

Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders

Wunderink, L. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319836566 · Cited by 24 · see citing works

Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5‐HT2A receptors in rats

Amada, N., Akazawa, H., Ohgi, Y., Maeda, K., Sugino, H., Kurahashi, N., Kikuchi, T., & Futamura, T. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12076 · Cited by 24 · see citing works

Bipolar disorder and dopamine dysfunction: an indirect approach focusing on tardive movement syndromes in a naturalistic setting

van Rossum, I., Tenback, D. E., & van Os, J. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-16 · Cited by 23 · see citing works

Explaining Attitudes and Adherence to Antipsychotic Medication: The Development of a Process Model

Wiesjahn, M., Jung, E., Lamster, F., Rief, W., & Lincoln, T. M. (2014) · Schizophrenia Research and Treatment · doi:10.1155/2014/341545 · Cited by 23 · see citing works

Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia

Nakata, Y., Kanahara, N., Kimura, H., Watanabe, H., & Iyo, M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000160 · Cited by 23 · see citing works

Gradually tapering off antipsychotics: lessons for practice from case studies and neurobiological principles

Horowitz, M. A., & Moncrieff, J. (2024) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000940 · Cited by 22 · see citing works

Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections

Debaveye, S., Smedt, D. D., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4247-2 · Cited by 22 · see citing works

Impairment of left ventricular function early in treatment with clozapine

Curto, M., Comparelli, A., Ciavarella, G. M., Gasperoni, C., Lionetto, L., Corigliano, V., Uccellini, A., Mancinelli, I., Ferracuti, S., Girardi, P., et al. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000085 · Cited by 22 · see citing works

Transient psychosis in women on clomiphene, bromocriptine, domperidone and related endocrine drugs

Seeman, M. V. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1060957 · Cited by 22 · see citing works

Drug Approval and Drug Effectiveness

Spielmans, G. I., & Kirsch, I. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185533 · Cited by 21 · see citing works

Addressing non‐adherence to antipsychotic medication: a harm‐reduction approach

ALDRIDGE, M. A. (2011) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2011.01809.x · Cited by 21 · see citing works

Powerful Choices: Peer Support and Individualized Medication Self-Determination

West, C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp053 · Cited by 21 · see citing works

At-risk mental state for psychosis: identification and current treatment approaches

Thompson, A. D., Marwaha, S., & Broome, M. R. (2016) · BJPsych Advances · doi:10.1192/apt.bp.115.015487 · Cited by 21 · see citing works

First, do no harm: Confronting the myths of psychiatric drugs

Barker, P., & Buchanan‐Barker, P. (2012) · Nursing Ethics · doi:10.1177/0969733011429017 · Cited by 20 · see citing works

Raising Adults as Children? A Report on Milieu Therapy in a Psychiatric Ward in Norway

Oeye, C., Bjelland, A. K., Skorpen, A., & Anderssen, N. (2009) · Issues in Mental Health Nursing · doi:10.1080/01612840802557246 · Cited by 20 · see citing works

Converting from brand-name to generic clozapine: A review of effectiveness and tolerability data

Bobo, W. V., Stovall, J., Knostman, M., Koestner, J., & Shelton, R. C. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080595 · Cited by 19 · see citing works

G protein-coupled receptor kinase 6/β-arrestin 2 system in a rat model of dopamine supersensitivity psychosis

Oda, Y., Tadokoro, S., Takase, M., Kanahara, N., Watanabe, H., Shirayama, Y., Hashimoto, K., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115593903 · Cited by 18 · see citing works

A quantitative review of the profile and time course of symptom change in schizophrenia treated with clozapine

Sherwood, M., Thornton, A. E., & Honer, W. G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112440513 · Cited by 17 · see citing works

Switching from conventional antipsychotics to ziprasidone: A randomized, open-label comparison of regimen strategies

Stip, É., Zhornitsky, S., Potvin, S., & Tourjman, V. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.010 · Cited by 17 · see citing works

Iatrogenia y prevención cuaternaria en salud mental

Lobo, A. O., & Rojo, V. (2011) · Revista Española de Salud Pública · doi:10.1590/s1135-57272011000600002 · Cited by 17 · see citing works

Recurrent clozapine and lorazepam withdrawal psychosis with catatonia

Wang, B. Z., Gupta, A., Bastiampillai, T. J., & Sani, F. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412444992 · Cited by 17 · see citing works

Effectiveness of blonanserin for patients with drug treatment-resistant schizophrenia and dopamine supersensitivity: A retrospective analysis

Tachibana, M., Niitsu, T., Watanabe, M., Hashimoto, T., Kanahara, N., Ishikawa, M., & Iyo, M. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.014 · Cited by 17 · see citing works

New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base

Ostuzzi, G., Papola, D., Gastaldon, C., & Barbui, C. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016001025 · Cited by 17 · see citing works

Effect of Citalopram in Combination with Omega-3 on Depression in Post- menopausal Women: A Triple Blind Randomized Controlled Trial

Masoumi, S. Z. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/19487.8597 · Cited by 17 · see citing works

Review article Does

Moncrieff, J. (2006)

Rapid Onset Psychosis Following Abrupt Clozapine Withdrawal

Shlovitz, T. M., Welke, T. L., Phillip, D., Richard, D., Sramek, J. J., Kurtz, M., & Cutler, N. R. (2015)

Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal

Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104 · see citing works

Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal

Ekblom, B., Eriksson, K., & Lindstr�m, L. H. (1984) · Psychopharmacology · doi:10.1007/bf00464798 · Cited by 88 · see citing works

Rapid Onset Psychosis after Reduction of the Risperidone Dose

Molina, J. D. D., Solé, S., de Pablo, S., Lopez-Munoz, F. J., Santana, G., & Álamo, C. D. (2008) · Pharmacopsychiatry · doi:10.1055/s-2008-1076722 · Cited by 1 · see citing works